Fractyl Health Q3 net loss $23.2M; cash $84.7M; Revita studies on track

FRACTYL HEALTH, INC.

2024-Q3 EPS reported -$1.09 revenue$90,000

Net loss $23.2M vs $15.7M YoY; R&D expense $19.0M (up from $9.4M) on clinical progress.
Cash and equivalents $84.7M; expected to fund operations into Q4 2025.
REMAIN-1 mid-point analysis expected Q2 2025; REVEAL-1 open-label data start Q4 2024.
REVITALIZE-1 topline data expected mid-2025; RJVA-001 CTA submission by YE 2024.
Nominated RJVA-002, first smart GIP/GLP-1 pancreatic gene therapy candidate for obesity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.